Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer

Summary

The investigators propose a phase II clinical trial with the objective to investigate the potential clinical interest to associate regorafenib with a metronomic chemotherapy combining capecitabine, cyclophosphamide and low-dose aspirin, for the treatment of patients with metastatic colorectal cancer. The main objective of the study will be to achieve 15% of objective response rate in patients treated with multimodal metronomic chemotherapy and regorafenib.

Timeline

Start

2020-10-16

Primary completion

2023-12-13

Completion

2023-12-13

Publications

• El Kaddissi A, Vienot A, Fumet JD, Meurisse A, Nguyen T, Klajer E, Bouard A, Spehner L, Fein F, Stouvenot M, Dochy E, Rebucci-Peixoto M, Almotlak H, Henriquez J, Selmani Z, Vernerey D, Hervouet E, Folletet A, Kim S, Ghiringhelli F, Borg C. Regorafenib and metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer: results from the REPROGRAM-01 single-arm phase II trial. ESMO Gastrointest Oncol. 2025 Dec 3;10:100270. doi: 10.1016/j.esmogo.2025.100270. eCollection 2025 Dec.

Drugs

Indications